Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 6
2015 5
2019 2
2020 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Turoctocog alfa (NovoEight)--from design to clinical proof of concept.
Ezban M, Vad K, Kjalke M. Ezban M, et al. Eur J Haematol. 2014 Nov;93(5):369-76. doi: 10.1111/ejh.12366. Epub 2014 May 28. Eur J Haematol. 2014. PMID: 24797664 Free PMC article. Review.
Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. ...Half-lives of 7.2 0.9 h in F8-KO mice and 8.9 1.8 h haemophilia A dogs supported that turoctocog alfa bound to VWF after inf …
Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. . …
Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H, Hirose J. Takedani H, et al. Drug Des Devel Ther. 2015 Mar 24;9:1767-72. doi: 10.2147/DDDT.S57967. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25848213 Free PMC article. Review.
Turoctocog alfa is the first B-domain-truncated third generation recombinant coagulation factor VIII (FVIII) product. ...Three clinical trials are ongoing to assess the long-term safety and efficacy of turoctocog alfa for PTPs and previously untreated …
Turoctocog alfa is the first B-domain-truncated third generation recombinant coagulation factor VIII (FVIII) product. ...Three …
Turoctocog alfa for the treatment of hemophilia a.
Vakil NH, Fujinami N, Martin-Stone S. Vakil NH, et al. Pharmacotherapy. 2014 Oct;34(10):1091-101. doi: 10.1002/phar.1469. Epub 2014 Jul 23. Pharmacotherapy. 2014. PMID: 25052207 Review.
Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market until 2015. Turoctocog alfa appears to be a safe and effective alternative to currently available recombinant FVIII concentra …
Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market …
Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Tiede A, Klamroth R, Oldenburg J. Tiede A, et al. Hamostaseologie. 2015;35(4):364-71. doi: 10.5482/HAMO-15-06-0019. Epub 2015 Aug 14. Hamostaseologie. 2015. PMID: 26271775 Review.
Turoctocog alfa (NovoEight) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine sulphation, similar to plasma-derived FVIII products. The manufacturing process includes double nanofiltration with a 20-nm pore size and im …
Turoctocog alfa (NovoEight) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine …
An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
Boban A, Hermans C. Boban A, et al. Expert Rev Hematol. 2020 Apr;13(4):303-311. doi: 10.1080/17474086.2020.1740586. Epub 2020 Mar 14. Expert Rev Hematol. 2020. PMID: 32153219 Review.
Advancements in biotechnology have enabled development of recombinant factor concentrates, which thus minimize the risk of transmitting infectious diseases. Turoctocog alfa (NovoEight, Novo Nordisk A/S, Bagsvaerd, Denmark) was the first third-generation B-domain tru …
Advancements in biotechnology have enabled development of recombinant factor concentrates, which thus minimize the risk of transmitting infe …
An overview of turoctocog alfa pegol (N8-GP; ESPEROCT() ) assay performance: Implications for postadministration monitoring.
Ezban M, Hansen M, Kjalke M. Ezban M, et al. Haemophilia. 2020 Jan;26(1):156-163. doi: 10.1111/hae.13897. Epub 2019 Dec 6. Haemophilia. 2020. PMID: 31809565 Free PMC article. Review.
Certain silica-based APTT reagents have previously been shown to underestimate FVIII activity with the polyethylene glycol (PEG)-conjugated product turoctocog alfa pegol (N8-GP [ESPEROCT() ]; Novo Nordisk A/S). As a wide range of assay reagents are used in clinical …
Certain silica-based APTT reagents have previously been shown to underestimate FVIII activity with the polyethylene glycol (PEG)-conjugated …
The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight), in patients with hemophilia A.
Jiménez-Yuste V, Lejniece S, Klamroth R, Suzuki T, Santagostino E, Karim FA, Saugstrup T, Møss J. Jiménez-Yuste V, et al. J Thromb Haemost. 2015 Mar;13(3):370-9. doi: 10.1111/jth.12816. Epub 2015 Feb 13. J Thromb Haemost. 2015. PMID: 25495795 Free article. Review.
BACKGROUND: Turoctocog alfa (NovoEight()) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients with hemophilia A. ...RESULTS: Data from 76 patients (aged 1-60 years) enrolled globally across six clinical trials were included, totalin …
BACKGROUND: Turoctocog alfa (NovoEight()) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patient …
Updates from guardian™: a comprehensive registration programme.
Ozelo MC. Ozelo MC. Eur J Haematol. 2015 Dec;95 Suppl 81:22-9. doi: 10.1111/ejh.12648. Eur J Haematol. 2015. PMID: 26679394 Review.
Turoctocog alfa is an approved B-domain truncated recombinant factor VIII concentrate for adults and children with haemophilia A. ...This article reviews the clinical development of turoctocog alfa with reference to the guardian() clinical programme, d …
Turoctocog alfa is an approved B-domain truncated recombinant factor VIII concentrate for adults and children with haemophilia …
A new recombinant factor VIII: from genetics to clinical use.
Santagostino E. Santagostino E. Drug Des Devel Ther. 2014 Dec 12;8:2507-15. doi: 10.2147/DDDT.S73241. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25548513 Free PMC article. Review.
Culture conditions and a five-step purification process have been developed to optimize the safety of turoctocog alfa. The results of two pilot clinical trials using turoctocog alfa confirmed high safety levels, with no patient developing inhibitors du …
Culture conditions and a five-step purification process have been developed to optimize the safety of turoctocog alfa. The res …
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
Schiavoni M, Napolitano M, Giuffrida G, Coluccia A, Siragusa S, Calafiore V, Lassandro G, Giordano P. Schiavoni M, et al. Front Med (Lausanne). 2019 Dec 3;6:261. doi: 10.3389/fmed.2019.00261. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31850352 Free PMC article. Review.
Third-generation products include two modified octocog alfa molecules (Advate, Shire; Kovaltry, Bayer) as well as the B domain-deleted rFVIII (BDD-rFVIII) moroctocog alfa (ReFacto-Pfizer). The B domain-truncated (BDT-rFVIII) turoctocog alfa (NovoEight, Novo Nordisk) …
Third-generation products include two modified octocog alfa molecules (Advate, Shire; Kovaltry, Bayer) as well as the B domain-deleted rFVII …
14 results